Thera-SAbDab

LENZILUMAB

> Structural Summary

Therapeutic	Lenzilumab
Target	CSF2
Heavy Chain	QVQLVQSGAEVKKPGASVKVSCKASGYSFTNYYIHWVRQAPGQRLEWMGWINAGNGNTKYSQKFQGRVTITRDTSASTAYMELSSLRSEDTAVYYCVRRQRFPYYFDYWGQGTLVTVSS
Light Chain	EIVLTQSPATLSVSPGERATLSCRASQSVGTNVAWYQQKPGQAPRVLIYSTSSRATGITDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQFNKSPLTFGGGTKVEIK
100% seqID Fv Structure	None
99% seqID Fv Structure	None
95-98% seqID Fv Structure	None

There are currently no PDB structures close in sequence to this therapeutic Fv. Click here to build a model with ABodyBuilder2.

> SAbPred Links

Follow these links to our prediction tools:

Model the variable domain structure with ABodyBuilder2
Test for possible therapeutic developability issues with TAP
Assign canonical forms by sequence with SCALOP
Number the sequences in any numbering scheme with ANARCI: [heavy] [light]

Format	Lenzilumab
Isotype	Lenzilumab
Highest Clinical Trial (Feb '25)	Preregistration
Estimated Status (Feb '25)	Active
Recorded Developmental Technology	Humaneering Technology
INN Year Proposed	2014
INN Year Recommended	2015
Companies Involved	Humanigen, KaloBios Pharmaceuticals
Conditions Approved	na
Conditions Active	COVID-19, Cytokine release syndrome, B-cell lymphoma, Drug hypersensitivity, Precursor cell lymphoblastic leukaemia-lymphoma, Graft-versus-host disease
Conditions Discontinued	Asthma, Rheumatoid arthritis, Chronic myelomonocytic leukaemia, Solid tumours
Notes

Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]

Our privacy policy